October 28, 2021

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

Quarterly net revenues of $133.6 million with 77% gross margin Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across… Read More
learn more
October 28, 2021

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

Final data from INNOVATE-3 trial anticipated in 2023 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer. “This… Read More
learn more
October 21, 2021

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting

Highlights include presentations by external authors studying the effects of concurrent Tumor Treating Fields and chemoradiation for patients with newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 15 presentations on Tumor Treating Fields (TTFields) will be featured at the American Society for Radiation Oncology (ASTRO)… Read More
learn more
October 4, 2021

Novocure to Report Third Quarter 2021 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and nine… Read More
learn more
October 4, 2021

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Final data collection is expected in the first half of 2022 ST. HELIER, Jersey & SHANGHAI–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage… Read More
learn more
September 14, 2021

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC). Pancreatic ductal adenocarcinoma (PDAC) is the most… Read More
learn more
September 9, 2021

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer

NovoTTF-200T is a Tumor Treating Fields delivery system intended for use together with atezolizumab and bevacizumab for the treatment of patients with advanced liver cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T… Read More
learn more
September 2, 2021

Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021. Ms. Cordova and Mr. Shah will take part in a fireside chat at 10:40 a.m. Read More
learn more
September 1, 2021

Novocure Appoints Bill Burke as Chief Human Resources Officer

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of Novocure’s team members to our anticipated growth. Mr. Burke joined Novocure in 2014 and most recently served as the… Read More
learn more
July 29, 2021

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter… Read More
learn more